Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) Versus PCV for glioblastoma multiforme

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3878-3884

  Levin, Victor A ^a   Uhm, Joon H ^a   Jaeckle, Kurt A ^a   Choucair, Ali ^b   Flynn, Patrick J ^c   Yung, W K Alfred ^a   Prados, Michael D ^d   Bruner, Janet M ^a   Chang, Susan M ^d   Kyritsis, Athanassios P ^a   Gleason, Mary Jo ^a   Hess, Kenneth R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MARSHFIELD CLINIC   (United States)

^c Metro Minnesota CCOP   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; EFLORNITHINE; GADOLINIUM; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; OTOTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EFLORNITHINE; FEMALE; GLIOBLASTOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; PROSPECTIVE STUDIES; TIME FACTORS; VINCRISTINE; VINDESINE;

EID: 0033755187     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Initial characterization of a HTC cell variant partially resistant to the antiproliferative effect of ornithine decarboxylase inhibitors
2. Antiproliferative properties of DL-α-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase
3. Inhibition of EMT6 rumor growth by interference with polyamine biosynthesis; effects of α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase
4. Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice
5. Copenhagen rat prostate tumor ornithine decarboxylase (ODC) activity and the effect of the ODC inhibitor α difluoromethyl ornithine
6. Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia
7. Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by α-difluoromethylornithine, an ornithine decarboxylase inhibitor
8. Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by α-difluoromethylornithine, an ornithine decarboxylase inhibitor
9. Differential potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea by α-difluoromethylornithine in chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro
10. Inhibition of polyamine biosynthesis by α-difluoromethyl ornithine potentiates the cytotoxic effects of 1-β-D-arabinofuranoxylcytosine in HeLa cells
11. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and α-difluoromethylornithine
12. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
13. Treatment of recurrent gliomas with eflornithine
14. Response criteria for Phase II studies of supratentorial malignant glioma
15. Computed tomography in the evaluation of malignant glioma before and after therapy
16. Further evidence for the use of polyamines as biochemical markers for malignant tumors
17. Polyamines in human brain tumors. A correlative study between tumor, cerebrospinal fluid and red blood cell free polyamine levels
18. Putrescine as a biochemical marker of malignant brain tumors
19. Polyamine metabolism in gliomas
20. Polyamine metabolism in experimental brain tumors of rat
21. Time dependence of the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity caused by α-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells
22. 1 to S transition
23. Effects of DFMO on glioma cell proliferation, migration and invasion in vitro
24. Difluoromethylornithine enhanced uptake of tritiated putrescine in 9L rat brain tumors
25. 3H]putrescine uptake on 9L tumor cell growth and colony forming efficiency
26. Effect of α-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity. DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro
27. CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs
28. Brain, CSF, and tumor pharmacokinetics of α-difluoromethylornithine in rats and dogs
29. Inhibition of the growth of U-251 human glioblastoma in nude mice by polyamine deprivation
30. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues
31. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-X(L) and caspase-3-like proteases
32. Putrescine metabolism in human brain tumors
33. The additive effect of α-difluoromethylornithine (DFMO) and radiation therapy on a rat glioma model
34. α-Difluoromethylornithine increases the antitumor effect of cis-diamminedichloroplatinum in G-XII rat glioma
35. Growth inhibitory effect of recombinant α and β interferon on human glioma cells
36. Phase II trial of recombinant interferon-α-2a and eflornithine in patients with recurrent glioma